

AI Diagnostics Platform — Phase 2: MVP Development

GLOBAL PHARMACEUTICAL CLIENT · NDA

Overall Status:
AMBERREPORT DATE
14 June 2025REPORTING PERIOD
Week 14 of 26PROJECT MANAGER
Hanna KlimushkaNEXT MILESTONE
MVP Release · 28 JunACTIVE FTES
22

EXECUTIVE SUMMARY

Delivery is on track across two of three workstreams, with the ML Model Development stream currently Amber due to a two-day delay in training data validation — a mitigation plan is in place and the MVP milestone remains achievable by 28 June. Budget is tracking within tolerance at 71% consumed against 54% of timeline elapsed; the £18k variance is attributable to additional cloud compute costs for model training, which have been escalated and approved by the sponsor. SOC 2 compliance controls remain embedded with zero audit findings raised to date.

KEY METRICS

SPRINT VELOCITY

87%

Target: 85% · ✓ On track

BUDGET CONSUMED

71%

£342k of £480k · ⚠ Amber

TIMELINE PROGRESS

54%

Wk 14 of 26 · On schedule

MILESTONES

6/8

On track · 1 delayed · 1 upcoming

OPEN RISKS

4


1 High · 2 Medium · 1 Low

WORKSTREAM STATUS

WORKSTREAM	LEAD	RAG	PROGRESS	COMMENT
Data Engineering	S. Marchenko	GREEN	72%	Pipeline validated; NLP extraction QA complete
ML / Model Dev	O. Kovalenko	AMBER	58%	Training data validation delayed 2 days; mitigation active
Platform & UX	Y. Bondar	GREEN	68%	Dashboard v2 signed off; UAT prep in progress
Compliance & QA	G. Petrenko	GREEN	80%	SOC 2 controls embedded; zero audit findings

SPRINT VELOCITY (STORY POINTS)

LAST 6 SPRINTS VS TARGET (85 SP)



SAMPLE

This is an anonymised work sample. All project names, client details, and personnel are fictional.

TOP RISKS

RISK	IMPACT	PROB.	RAG	OWNER	MITIGATION
Training data validation delay — may push ML milestone by 3 days	High	Medium	AMBER	O. Kovalenko	Additional data engineer assigned; daily checkpoint instated
Cloud compute cost overrun — model training exceeding budget estimate	Medium	High	AMBER	H. Klimushka	£18k variance approved by sponsor; cost cap alert configured
UAT resource availability — client clinical team availability in Wk 17	Medium	Low	GREEN	H. Klimushka	UAT schedule confirmed; backup reviewer identified

KEY DECISIONS THIS WEEK

- ✓

Approved £18k cloud compute overspend — absorbed within contingency reserve

Decision owner: Sponsor · Ratified 11 Jun
- ✓

Dashboard v2 UX signed off by clinical lead — proceeding to UAT build

Decision owner: Product Owner · Ratified 12 Jun
- ✓

Agreed to defer conversational AI interface to Phase 3 — descoped from MVP

Decision owner: H. Klimushka + Sponsor · Ratified 13 Jun

ACTIONS DUE NEXT WEEK

- Complete training data validation and rerun ML baseline

Owner: O. Kovalenko

20 Jun
- Finalise UAT test cases and send to clinical team for review

Owner: Y. Bondar

18 Jun
- Deliver fortnightly executive report to C-level sponsor

Owner: H. Klimushka

21 Jun
- Update RAID log and circulate to all workstream leads

Owner: H. Klimushka

17 Jun

SAMPLE

This is an anonymised work sample. All project names, client details, and personnel are fictional.